FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

Guidance on Resuming Normal Drug/Biologic Manufacturing

FDA issues a temporary guidance entitled Resuming Normal Drug and Biologics Manufacturing Operations During the COVID-19 Public Health Emergency to he...

Federal Register

Regulatory Review Period for Dyaxs Takhzyro

Federal Register notice: FDA determines for patent extension purposes the regulatory review period for Dyax Corp.s Takhzyro, indicated for prophylaxis...

Biologics

Covid-19 Vaccine Emergency Use Guide Soon: FDA

FDA says it will soon issue a guidance for sponsors to request an Emergency Use Authorization for their vaccines, including recommendations on the dat...

Human Drugs

Pharmacy Plus Warning on Unapproved Covid Products

FDA issues Pharmacy Plus (dba Vital Care Compounder) a Warning Letter for offering unapproved drug products for prophylaxis and treatment of, and reco...

Biologics

CBER Untitled Letter Over Unapproved Cellular Product

CBER sends an untitled letter to Laguna Beach Aesthetics, Cosmetic Dermatology and Laser Center over its unapproved cellular product derived from adip...

Human Drugs

RLC Labs Recalls Subpotent Thyroid Products

RLC Labs recalls 483 lots of Nature-Throid and WP Thyroid because FDA testing of samples from six lots found them to be subpotent.

Medical Devices

Avinger Chronic Total Occlusion Device Cleared

FDA clears an Avinger 510(k) for its TigerEye image-guided chronic total occlusion crossing system.

Medical Devices

De Novo Pathway for Neuro, Physical Medicine Devices

FDA holds a Webinar to explain the de novo pathway for use with new neurological and physical medicine devices.

Federal Register

Regulatory Review Period for Senseonics Glucose Monitor

Federal Register notice: FDA determines for patent extension purposes the regulatory review period for Senseonics Eversense Continuous Glucose Monitor...

Federal Register

EUAs Announced for Four Covid-19 Drugs

Federal Register notice: FDA announces the issuance of four emergency use authorizations for drugs for use during the Covid-19 pandemic.